Aptargroup

AptarGroup Reports Q4 2025 Earnings: 14% Sales Growth and 5% Core Sales Increase

AptarGroup Beats Earnings and Revenue Estimates, Q4 Earnings Surprise +1.22%, Q4 Revenue Surpasses Estimates by 8.19%

AptarGroup Q4 Income Falls to $74.34mln, Revenue Up 13.5% to $962.73mln

阿普达集团

Aptar Q4 sales up 14% YoY, core sales up 5%, EPS down 24%.

Aptargroup's 15-min chart triggered RSI Oversold, KDJ Golden Cross signal.

Catalyst<ul> <li>Most analysts rate ATR Neutral, indicating some level of cautious optimism about its market position.</li> <li>ATR maintains strong cash reserves relative to market value, providing a financial buffer.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li> <li>Fund flows indicate an overall negative trend, with large and extra-large orders showing outflows.</li></ul>

Key Factors

AptarGroup reported Q4 2025 sales of $963 million, up 14% year over year, with core sales increasing by 5%. Adjusted EBITDA margin for Q4 2025 declined to 19.8% from 23% in the prior year, reflecting rising costs and a mix shift. AptarGroup's Q4 2025 earnings per share were $1.13, a 24% decline from the prior year, while adjusted EPS was $1.25. The company guided for next quarter earnings per share between $1.13 and $1.21 and noted a $65 million headwind in its emergency medicine segment. AptarGroup's stock dipped after earnings despite beating revenue and EPS estimates, due to weak margin performance and cautious guidance.

ATR News